Clinical Trials Using Alisertib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Alisertib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Alisertib with or without Fulvestrant in Treating Patients with Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

    This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may work better in treating patients with breast cancer.
    Location: 10 locations

  • Alisertib Alone or in Combination with Chemotherapy and Radiation Therapy in Treating Younger Patients with Recurrent, Progressive, or Newly Diagnosed Central Nervous System Atypical Teratoid Rhabdoid Tumors or Extra-Central Nervous System Malignant Rhabdoid Tumors

    This phase II trial studies how well alisertib alone or in combination with chemotherapy and radiation therapy works in treating younger patients with central nervous system (CNS) atypical teratoid rhabdoid tumors that are newly diagnosed; have returned; or are growing, spreading, or getting worse or extra-CNS malignant rhabdoid tumors that have returned or are growing, spreading, or getting worse. Alisertib may stop the growth of cancer cells by blocking a protein called aurora kinase A that is needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses x-rays to kill tumor cells. Giving alisertib alone or with chemotherapy and radiation therapy may be effective in treating patients with rhabdoid tumors.
    Location: 10 locations

  • Alisertib and Osimertinib for the Treatment of EGFR-Mutated Stage IV Lung Cancer

    This phase I / Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may may stop the growth of tumor cells by blocking a specific protein that researchers believe may be important for treating lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and / or bad, it has on EGFR-mutated lung cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Sapanisertib and Alisertib in Treating Patients with Incurable Refractory Solid Tumors or Metastatic Triple-Negative Breast Cancer

    This phase Ib trial studies the side effects and best dose of sapanisertib and alisertib in treating patients with solid tumors that have no treatment currently available and do not respond to treatment or triple-negative breast cancer (TNBC) that has spread to other parts of the body. Sapanisertib and alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Colorado Hospital, Aurora, Colorado